The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ADMS, QD and GERN

NEW YORK, NY / ACCESSWIRE / January 27, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Adamas Pharmaceuticals, Inc. (NASDAQGM:ADMS)
Class Period: August 8, 2017 to September 30, 2019
Lead Plaintiff Deadline: February 10, 2020

The ADMS lawsuit alleges that Adamas Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) health insurers were excluding Adamas's primary product, GOCOVRI, from their prescription formularies or requiring patients to use "step therapy" – i.e., making patients try immediate-release amantadine prior to covering GOCOVRI; (2) the rapid increase in physicians prescribing GOCOVRI during the Class Period was not due to its efficacy; and (3) as a result of the foregoing, the Company's financial statements about Adamas's business, operations, and prospects were materially false and misleading at all relevant times.

Learn about your recoverable losses in ADMS: http://www.kleinstocklaw.com/pslra-1/adamas-pharmaceuticals-inc-loss-submission-form?id=5358&from=1

Qudian Inc. (NYSE:QD)
Class Period: December 13, 2018 to January 15, 2020
Lead Plaintiff Deadline: March 23, 2020

The complaint alleges that throughout the class period Qudian Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) regulatory developments in China threatened to negatively impact Qudian's fiscal full year 2019 ("FY19") financial results; (ii) Qudian's business was unprepared to mitigate the risks associated with these regulatory changes; (iii) as a result, Qudian's loan portfolio was plagued by growing delinquency rates; (iv) all of the foregoing made Qudian's repeated assertions concerning its FY19 financial guidance unrealistic; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in QD: http://www.kleinstocklaw.com/pslra-1/qudian-inc-loss-submission-form?id=5358&from=1

Geron Corporation (NASDAQ:GERN)
Class Period: March 19, 2018 to September 26, 2018
Lead Plaintiff Deadline: March 23, 2020

The filed complaint alleges that defendants misled investors regarding a drug called imetelstat, which was intended to treat certain cancers that occur in bone marrow. Specifically, defendants misled investors about the results of a clinical drug study of imetelstat called IMbark. That study was designed to ascertain whether imetelstat helped patients with a cancer called myelofibrosis.

Learn about your recoverable losses in GERN: http://www.kleinstocklaw.com/pslra-1/geron-corporation-et-al-loss-submission-form?id=5358&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 574188